Morgan Stanley Cuts Exelon (NASDAQ:EXC) Target Price to $52.00
Exelon (NASDAQ:EXC – Get a rating) had its price target reduced by Morgan Stanley stock analysts from $54.00 to $52.00 in a report on Thursday, Benzinga reports. The company currently has an “overweight” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 24.79% from the company’s current price.
Several other research analysts also commented on EXC. KeyCorp cut its price target on Exelon from $53.00 to $45.00 and set an “overweight” rating on the stock in a Tuesday, July 19 report. Wells Fargo & Company cut its price target on Exelon shares from $52.00 to $49.00 and set an “equal weight” rating on the stock in a Thursday, Aug. 4, report. BMO Capital Markets raised its price target on Exelon shares from $49.00 to $51.00 and gave the company an “outperform” rating in a Thursday, Aug. 4, report. UBS Group cut its price target on Exelon shares from $54.00 to $49.00 and set a “buy” rating on the stock in a Thursday, June 30 report. Finally, Mizuho raised its price target on Exelon shares from $46.00 to $47.00 and gave the company a “buy” rating in a Wednesday, August 31 report. Seven research analysts gave the stock a hold rating and seven gave the company a buy rating. According to MarketBeat.com, the stock currently has a “moderate buy” consensus rating and an average price target of $48.23.
Performance of Exelon shares
Shares of EXC opened at $41.67 on Thursday. The company has a fifty-day moving average price of $44.89. The company has a quick ratio of 0.84, a current ratio of 0.91 and a debt ratio of 1.53. The stock has a market capitalization of $40.86 billion, a price/earnings ratio of 15.38, a P/E/G ratio of 2.58 and a beta of 0.57. Exelon has a fifty-two week low of $33.93 and a fifty-two week high of $50.71.
Exelon (NASDAQ:EXC – Get Rating) last released its quarterly results on Wednesday August 3rd. The company reported EPS of $0.44 for the quarter, missing the consensus estimate of $0.46 per ($0.02). Exelon had a return on equity of 10.38% and a net margin of 9.45%. The company posted revenue of $4.24 billion for the quarter, versus $4.12 billion expected by analysts. On average, stock analysts expect Exelon to post earnings per share of 2.27 for the current year.
Hedge funds weigh on Exelon
Several hedge funds and other institutional investors have recently changed their positions in EXC. Wellington Management Group LLP increased its stake in Exelon by 20.1% in the first quarter. Wellington Management Group LLP now owns 93,209,957 shares of the company worth $4,439,591,000 after acquiring an additional 15,573,269 shares in the last quarter. Vanguard Group Inc. increased its position in Exelon shares by 2.8% during the first quarter. Vanguard Group Inc. now owns 86,862,993 shares of the company worth $4,137,284,000 after purchasing an additional 2,365,787 shares in the last quarter. BlackRock Inc. increased its stake in Exelon shares by 2.4% during the first quarter. BlackRock Inc. now owns 77,171,172 shares of the company worth $3,675,664,000 after purchasing an additional 1,794,762 shares last quarter. Capital International Investors increased its stake in Exelon by 0.8% in the fourth quarter. Capital International Investors now owns 59,795,610 shares of the company valued at $3,453,694,000 after purchasing an additional 491,087 shares in the last quarter. Finally, State Street Corp increased its stake in Exelon by 4.2% in the second quarter. State Street Corp now owns 58,535,397 shares of the company valued at $2,652,824,000 after purchasing an additional 2,339,235 shares last quarter. Hedge funds and other institutional investors own 82.70% of the company’s shares.
(Get a rating)
Exelon Corporation, a utility holding company, is engaged in the generation, delivery and marketing of energy in the United States and Canada. It has nuclear, fossil, wind, hydroelectric, biomass and solar power plants. The company also sells electricity to wholesale and retail customers; and sells natural gas, renewable energy and other energy-related products and services.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to firstname.lastname@example.org.
Before you consider Exelon, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Exelon wasn’t on the list.
While Exelon currently enjoys a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here